Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
Background: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alt...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2022-05-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/77146 |